🇺🇸 FDA
Patent

US 9677076

Modulation of hepatitis B virus (HBV) expression

granted A61PA61P1/16A61P29/00

Quick answer

US patent 9677076 (Modulation of hepatitis B virus (HBV) expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P1/16, A61P29/00, A61P31/14, A61P31/20